Skip to main content
S&P 5007,773.95+0.66%DOW51,267.90+0.18%NASDAQ27,477.31+1.05%BTC$85,823.00-0.87%ETH$2,714.23-0.50%GOLD$4,166.20+0.23%OIL$89.41-0.02%
Smart Investors Daily
SID Premium
WX

OTC · WXXWY

WuXi Biologics (Cayman) Inc.

Healthcare · Biotechnology

$14.30

Up+$0.37 (+2.66%)

Updated Oct 6, 2026, 7:21 AM

SID Score

5.5/10

Composite research score

Smart Money

46/100

Neutral

Market cap
17.21B
P/E ratio
30.57
Dividend yield
0.00%
52-week range
— – —
Volume
4.59K
Avg. volume
37.66K

Price performance · WXXWY

WXXWY price history

1M range · 0 trading sessions · Daily adjusted prices

WXXWY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest WXXWY news

The latest Smart Investors Daily articles mentioning WXXWY.

Stock researchCompany · Overview

WXXWY research

Overview

Company profile and research snapshot.

Company profile

WUXI BIOLOGICS UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$10.10
Implied upside
—
Analysts
33
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption

Biologics, biosimilars and personalized therapies are fueling CDMO outsourcing, while AI, automation and single-use systems enable scalable, compliant protein production.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Manufacturing Services Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Recombinant Proteins Manufacturing Services Market to Reach US$15.3 Billion by 2030 The global recombinant proteins manufacturing services m

Yahoo · Sep 24, 2026

WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its drug substance (DS) and drug product (DP) manufacturing facilities at the Wuxi Mashan site successfully passed a two-week GMP inspection conducted by the U.S. Food and Drug Administration (FDA). The successful inspection further strengthens the Company's capabilities to ensure the reliable supply of its partners' commercial products to the U.S. market.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By